Kelowna, British Columbia – July 10, 2025 – TheNewswire - Rize Oncology Inc. (the “Company”), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, today announced that it has appointed Executive Chairperson Daren Graham as the Company’s interim Chief Executive Officer.

Mr. Graham’s appointment will be effective July 10, 2025 and coincides with the resignation of Roland Boivin as the Company’s chief executive officer and a director of the Company.  It is anticipated that Mr. Graham’s appointment will be for a limited period while the Board of Directors evaluates potential candidates to fill the position permanently.

Mr. Graham commented: “As we complete our transition into a focused oncology company, Roland has decided to pursue new opportunities. We are deeply grateful for the leadership he brought to Rize during a transformative time. From his instrumental role in our IPO and guiding us through our early days as a newly public company, to his leadership in facilitating our acquisition of STS-201, Roland played a key part in positioning Rize for long-term success. We’re pleased that he will continue to support the company as a consultant over the next six months, and on behalf of the entire team and Board, I want to thank him for his many contributions and wish him all the best in his next chapter.”

About Rize Oncology Inc.

Rize Oncology Inc. is a clinical-stage biopharmaceutical company dedicated to the development of STS-201, a small-molecule drug with a unique mechanism of action, currently being evaluated for its potential in treating soft tissue sarcoma and other cancers.​

Contact:

Daren Graham, Executive Chairman

(833) 294-4363 ext. 2

daren@rizeoncology.com

Forward-Looking Statements

This news release contains statements that constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. Forward-looking statements in this document include the Company’s expectation that Mr. Graham’s appointment will be on an interim basis only, and all other statements that are not statements of historical fact.

Although the Company believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements.

Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with general economic conditions; adverse industry events; future legislative and regulatory developments; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of the Company to implement its business strategies; competition; the ability of Rize to obtain and retain all applicable regulatory and other approvals and other assumptions, risks and uncertainties that may be disclosed in the Company’s continuous disclosure record from time to time.